These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3289388)

  • 21. Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity.
    Mattes E; Matthiessen HP; Turecek PL; Schwarz HP
    Vox Sang; 2001 Jul; 81(1):29-36. PubMed ID: 11520413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency.
    Barker AF; Iwata-Morgan I; Oveson L; Roussel R
    Chest; 1997 Sep; 112(3):607-13. PubMed ID: 9315791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency.
    Hubbard RC; Sellers S; Czerski D; Stephens L; Crystal RG
    JAMA; 1988 Sep; 260(9):1259-64. PubMed ID: 3261353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.
    Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
    McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
    Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration.
    Barker AF; Siemsen F; Pasley D; D'Silva R; Buist AS
    Chest; 1994 May; 105(5):1406-10. PubMed ID: 8181327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of neutrophil elastase, serum trypsin inhibitory activity, and smoking history as risk factors for chronic obstructive pulmonary disease in patients with MM, MZ, and ZZ phenotypes for alpha-antitrypsin.
    Galdston M; Melnick EL; Goldring RM; Levytska V; Curasi CA; Davis AL
    Am Rev Respir Dis; 1977 Nov; 116(5):837-46. PubMed ID: 303486
    [No Abstract]   [Full Text] [Related]  

  • 28. A matched-pair study of the leukocyte elastase-like activity in normal persons and in emphysematous patients with and without alpha 1-antitrypsin deficiency.
    Kramps JA; Bakker W; Dijkman JH
    Am Rev Respir Dis; 1980 Feb; 121(2):253-61. PubMed ID: 6965829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor.
    Weitz JI; Silverman EK; Thong B; Campbell EJ
    J Clin Invest; 1992 Mar; 89(3):766-73. PubMed ID: 1541671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of alpha-1-proteinase inhibitor. Pharmacokinetics and safety studies.
    Fournel MA; Newgren JO; Betancourt CM; Irwin RG
    Am J Med; 1988 Jun; 84(6A):43-7. PubMed ID: 3260072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of chronic obstructive pulmonary disease in patients with intermediate levels of alpha-antitrypsin.
    Klayton R; Fallat R; Cohen AB
    Am Rev Respir Dis; 1975 Jul; 112(1):71-5. PubMed ID: 238443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interrelationships between serum chemotactic factor inactivator, alpha 1-antitrypsin deficiency, and chronic obstructive lung disease.
    Lam S; Chan-Yeung M; Abboud R; Kreutzer D
    Am Rev Respir Dis; 1980 Mar; 121(3):507-12. PubMed ID: 6968167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase.
    Ogushi F; Fells GA; Hubbard RC; Straus SD; Crystal RG
    J Clin Invest; 1987 Nov; 80(5):1366-74. PubMed ID: 3500183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the liquid and lyophilized formulations of Prolastin®-C for Alpha
    Arora V; Cruz M; Lang J; Klos AM; Merritt WK; Price J; Taylor G; Vandeberg P; Wee K; Willis T
    Biologicals; 2019 Nov; 62():77-84. PubMed ID: 31522909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates.
    Silverman EK; Pierce JA; Province MA; Rao DC; Campbell EJ
    Ann Intern Med; 1989 Dec; 111(12):982-91. PubMed ID: 2596778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermediate alpha1-antitrypsin deficiency and chronic obstructive pulmonary disease in Yugoslavia.
    Kozarevic D; Laban M; Budimir M; Vojvodic N; Roberts A; Gordon T; McGee DL
    Am Rev Respir Dis; 1978 Jun; 117(6):1039-43. PubMed ID: 307352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional and antigenic concentrations of alpha-1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity.
    Stiskal JA; Ito S; Cox DW; Shennan AT; O'Brien KK; Kelly EN; Longley TB; Rabinovitch M; Dunn MS
    Biol Neonate; 1999 Sep; 76(3):134-43. PubMed ID: 10460951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients.
    King MB; Campbell EJ; Gray BH; Hertz MI
    Am J Respir Crit Care Med; 1994 Apr; 149(4 Pt 1):966-71. PubMed ID: 8143063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF; Miravitlles M
    Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term effect on lung function of alpha 1-protease inhibitor substitution therapy in COPD patients with Pi ZZ phenotype.
    Ulmer WT; Schmidt EW; Rasche B
    Eur Respir J Suppl; 1990 Mar; 9():21s-22s. PubMed ID: 2340047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.